Skip to main content

Advertisement

SpringerLink
Log in

The Clinicopathological and Molecular Associations of PD-L1 Expression in Non-small Cell Lung Cancer: Analysis of a Series of 10,005 Cases Tested with the 22C3 Assay

  • Original Article
  • Published:
Pathology & Oncology Research

Abstract

PD-L1 expression testing is mandatory prior to pembrolizumab prescription in non-small cell lung cancer. Our service offers PD-L1 testing using the PD-L1 IHC 22C3 pharmDx assay, in parallel with EGFR, ALK, ROS1 and (in some cases) KRAS testing. We correlate PD-L1 expression in 10,005 tumours with patient age and sex, with tumour histological subtypes, with the sampling modality and type of tissue, and with the presence of other molecular alterations. PD-L1 expression testing was performed using the aforementioned assay; tumour proportion scores (TPS) of 1 and 50% were taken as cut-offs for low and high positivity, respectively. EGFR testing was performed using the cobas® EGFR Mutation Test v2. ALK testing was performed using the VENTANA ALK (D5F3) CDx Assay. KRAS testing was performed using pyrosequencing. TPS <1% was seen in 44.4% of tumours, 1–49% in 25.0% and ≥ 50% in 30.6%. We identified no significant relationship with age. Female patients were slightly more likely to express PD-L1. Poorly-differentiated tumour histology and ALK translocation were significantly associated with PD-L1 expression. Rare EGFR mutations tended to be associated with PD-L1 expression. Pleural and nodal metastases were more likely to express PD-L1 than primary tumours, but biopsy and cytological specimens did not show different PD-L1 expression rates. Our data show that the means of acquiring a tumour sample (biopsy versus cytology) does not have a significant impact on PD-L1 expression. However, we found that certain metastatic sites were associated with significantly higher expression rates, which has substantial implications for selection of tissue for testing.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR, Investigators K (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung Cancer. N Engl J Med 375(19):1823–1833. https://doi.org/10.1056/NEJMoa1606774

    Article  CAS  PubMed  Google Scholar 

  2. Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G Jr, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387(10027):1540–1550. https://doi.org/10.1016/S0140-6736(15)01281-7

    Article  CAS  PubMed  Google Scholar 

  3. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L, Investigators K (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372(21):2018–2028. https://doi.org/10.1056/NEJMoa1501824

    Article  PubMed  Google Scholar 

  4. Cho J, Zhou W, Choi YL, Sun JM, Choi H, Kim TE, Dolled-Filhart M, Emancipator K, Rutkowski MA, Kim J (2015) 26OMolecular epidemiology study of PD-L1 expression in patients (pts) with EGFR-mutant NSCLC. Ann Oncol 26(suppl_9):ix8. https://doi.org/10.1093/annonc/mdv518.01

    Article  Google Scholar 

  5. Salanova R, Pereyra JCC, Leguina L, Bena A, Barberis M, Vargas R, RJd T, Kreimberg K, Powazniak Y (2017) Epidemiology of PD-L1 and ALK expression and EGFR mutational status in Argentinian patients with lung cancer. J Clin Oncol 35(15_suppl):e20565. https://doi.org/10.1200/JCO.2017.35.15_suppl.e20565

    Article  Google Scholar 

  6. Sorensen SF, Zhou W, Dolled-Filhart M, Georgsen JB, Wang Z, Emancipator K, Wu D, Busch-Sorensen M, Meldgaard P, Hager H (2016) PD-L1 expression and survival among patients with advanced non-small cell lung Cancer treated with chemotherapy. Transl Oncol 9(1):64–69. https://doi.org/10.1016/j.tranon.2016.01.003

    Article  PubMed  PubMed Central  Google Scholar 

  7. Pan Y, Zheng D, Li Y, Cai X, Zheng Z, Jin Y, Hu H, Cheng C, Shen L, Wang J, Ji H, Sun Y, Zhou X, Chen H (2017) Unique distribution of programmed death ligand 1 (PD-L1) expression in east Asian non-small cell lung cancer. J Thorac Dis 9(8):2579–2586. https://doi.org/10.21037/jtd.2017.08.61

    Article  PubMed  PubMed Central  Google Scholar 

  8. Sun JM, Zhou W, Choi YL, Choi SJ, Kim SE, Wang Z, Dolled-Filhart M, Emancipator K, Wu D, Weiner R, Frisman D, Kim HK, Choi YS, Shim YM, Kim J (2016) Prognostic significance of PD-L1 in patients with non-small cell lung Cancer: a large cohort study of surgically resected cases. J Thorac Oncol 11(7):1003–1011. https://doi.org/10.1016/j.jtho.2016.04.007

    Article  CAS  PubMed  Google Scholar 

  9. Li C, Huang C, Mok TS, Zhuang W, Xu H, Miao Q, Fan X, Zhu W, Huang Y, Lin X, Jiang K, Hu D, Chen X, Huang P, Lin G (2017) Comparison of 22C3 PD-L1 expression between surgically resected specimens and paired tissue microarrays in non-small cell lung Cancer. J Thorac Oncol 12(10):1536–1543. https://doi.org/10.1016/j.jtho.2017.07.015

    Article  PubMed  Google Scholar 

  10. Cooper WA, Tran T, Vilain RE, Madore J, Selinger CI, Kohonen-Corish M, Yip P, Yu B, O'Toole SA, McCaughan BC, Yearley JH, Horvath LG, Kao S, Boyer M, Scolyer RA (2015) PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer 89(2):181–188. https://doi.org/10.1016/j.lungcan.2015.05.007

    Article  PubMed  Google Scholar 

  11. Rangachari D, VanderLaan PA, Shea M, Le X, Huberman MS, Kobayashi SS, Costa DB (2017) Correlation between classic driver oncogene mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 >/=50% expression in lung adenocarcinoma. J Thorac Oncol 12(5):878–883. https://doi.org/10.1016/j.jtho.2016.12.026

    Article  PubMed  PubMed Central  Google Scholar 

  12. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, Miller ML, Rekhtman N, Moreira AL, Ibrahim F, Bruggeman C, Gasmi B, Zappasodi R, Maeda Y, Sander C, Garon EB, Merghoub T, Wolchok JD, Schumacher TN, Chan TA (2015) Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348(6230):124–128. https://doi.org/10.1126/science.aaa1348

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Shimoji M, Shimizu S, Sato K, Suda K, Kobayashi Y, Tomizawa K, Takemoto T, Mitsudomi T (2016) Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1). Lung Cancer 98:69–75. https://doi.org/10.1016/j.lungcan.2016.04.021

    Article  PubMed  Google Scholar 

  14. Azuma K, Ota K, Kawahara A, Hattori S, Iwama E, Harada T, Matsumoto K, Takayama K, Takamori S, Kage M, Hoshino T, Nakanishi Y, Okamoto I (2014) Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann Oncol 25(10):1935–1940. https://doi.org/10.1093/annonc/mdu242

    Article  CAS  PubMed  Google Scholar 

  15. McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelekanou V, Rehman J, Velcheti V, Herbst R, LoRusso P, Rimm DL (2016) Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung Cancer. JAMA Oncol 2(1):46–54. https://doi.org/10.1001/jamaoncol.2015.3638

    Article  PubMed  PubMed Central  Google Scholar 

  16. Cha YJ, Kim HR, Lee CY, Cho BC, Shim HS (2016) Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status. Lung Cancer 97:73–80. https://doi.org/10.1016/j.lungcan.2016.05.001

    Article  PubMed  Google Scholar 

  17. Vieira T, Antoine M, Hamard C, Fallet V, Duruisseaux M, Rabbe N, Rodenas A, Cadranel J, Wislez M (2016) Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages. Lung Cancer 98:51–58. https://doi.org/10.1016/j.lungcan.2016.05.013

    Article  PubMed  Google Scholar 

  18. Ilie M, Long-Mira E, Bence C, Butori C, Lassalle S, Bouhlel L, Fazzalari L, Zahaf K, Lalvee S, Washetine K, Mouroux J, Venissac N, Poudenx M, Otto J, Sabourin JC, Marquette CH, Hofman V, Hofman P (2016) Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol 27(1):147–153. https://doi.org/10.1093/annonc/mdv489

    Article  CAS  PubMed  Google Scholar 

  19. Huynh TG, Morales-Oyarvide V, Campo MJ, Gainor JF, Bozkurtlar E, Uruga H, Zhao L, Gomez-Caraballo M, Hata AN, Mark EJ, Lanuti M, Engelman JA, Mino-Kenudson M (2016) Programmed cell death ligand 1 expression in resected lung adenocarcinomas: association with immune microenvironment. J Thorac Oncol 11(11):1869–1878. https://doi.org/10.1016/j.jtho.2016.08.134

    Article  PubMed  Google Scholar 

  20. Fang W, Hong S, Chen N, He X, Zhan J, Qin T, Zhou T, Hu Z, Ma Y, Zhao Y, Tian Y, Yang Y, Xue C, Tang Y, Huang Y, Zhao H, Zhang L (2015) PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival. Oncotarget 6(32):33019–33032. https://doi.org/10.18632/oncotarget.5028

    Article  PubMed  PubMed Central  Google Scholar 

  21. Calles A, Liao X, Sholl LM, Rodig SJ, Freeman GJ, Butaney M, Lydon C, Dahlberg SE, Hodi FS, Oxnard GR, Jackman DM, Janne PA (2015) Expression of PD-1 and its ligands, PD-L1 and PD-L2, in smokers and never smokers with KRAS-mutant lung Cancer. J Thorac Oncol 10(12):1726–1735. https://doi.org/10.1097/JTO.0000000000000687

    Article  CAS  PubMed  Google Scholar 

  22. Koh J, Go H, Keam B, Kim MY, Nam SJ, Kim TM, Lee SH, Min HS, Kim YT, Kim DW, Jeon YK, Chung DH (2015) Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status. Mod Pathol 28(9):1154–1166. https://doi.org/10.1038/modpathol.2015.63

    Article  CAS  PubMed  Google Scholar 

  23. Kitazono S, Fujiwara Y, Tsuta K, Utsumi H, Kanda S, Horinouchi H, Nokihara H, Yamamoto N, Sasada S, Watanabe S, Asamura H, Tamura T, Ohe Y (2015) Reliability of small biopsy samples compared with resected specimens for the determination of programmed death-ligand 1 expression in non--small-cell lung Cancer. Clin Lung Cancer 16(5):385–390. https://doi.org/10.1016/j.cllc.2015.03.008

    Article  CAS  PubMed  Google Scholar 

  24. Zhang Y, Wang L, Li Y, Pan Y, Wang R, Hu H, Li H, Luo X, Ye T, Sun Y, Chen H (2014) Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. Onco Targets Ther 7:567–573. https://doi.org/10.2147/OTT.S59959

  25. Uruga H, Bozkurtlar E, Huynh TG, Muzikansky A, Goto Y, Gomez-Caraballo M, Hata AN, Gainor JF, Mark EJ, Engelman JA, Lanuti MD, Mino-Kenudson M (2017) Programmed cell death ligand (PD-L1) expression in stage II and III lung adenocarcinomas and nodal metastases. J Thorac Oncol 12(3):458–466. https://doi.org/10.1016/j.jtho.2016.10.015

    Article  PubMed  Google Scholar 

  26. Tsao MS, Le Teuff G, Shepherd FA, Landais C, Hainaut P, Filipits M, Pirker R, Le Chevalier T, Graziano S, Kratze R, Soria JC, Pignon JP, Seymour L, Brambilla E (2017) PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer. Ann Oncol 28 (4):882–889. https://doi.org/10.1093/annonc/mdx003

  27. Toyokawa G, Takada K, Okamoto T, Kawanami S, Kozuma Y, Matsubara T, Haratake N, Takamori S, Akamine T, Katsura M, Yamada Y, Shoji F, Baba S, Kamitani T, Oda Y, Honda H, Maehara Y (2017) Relevance between programmed death ligand 1 and radiologic invasiveness in pathologic stage I lung adenocarcinoma. Ann Thorac Surg 103(6):1750–1757. https://doi.org/10.1016/j.athoracsur.2016.12.025

    Article  PubMed  Google Scholar 

  28. Wu S, Shi X, Sun J, Liu Y, Luo Y, Liang Z, Wang J, Zeng X (2017) The significance of programmed cell death ligand 1 expression in resected lung adenocarcinoma. Oncotarget 8(10):16421–16429. https://doi.org/10.18632/oncotarget.14851

    Article  PubMed  PubMed Central  Google Scholar 

  29. Cho JH, Zhou W, Choi YL, Sun JM, Choi H, Kim TE, Dolled-Filhart M, Emancipator K, Rutkowski MA, Kim J (2017) Retrospective molecular epidemiology study of PD-L1 expression in patients with EGFR-mutant non-small cell lung Cancer. Cancer Res Treat 50:95–102. https://doi.org/10.4143/crt.2016.591

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Zhang M, Li G, Wang Y, Wang Y, Zhao S, Haihong P, Zhao H, Wang Y (2017) PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis. Sci Rep 7(1):10255. https://doi.org/10.1038/s41598-017-10925-7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Ota K, Azuma K, Kawahara A, Hattori S, Iwama E, Tanizaki J, Harada T, Matsumoto K, Takayama K, Takamori S, Kage M, Hoshino T, Nakanishi Y, Okamoto I (2015) Induction of PD-L1 expression by the EML4-ALK Oncoprotein and downstream signaling pathways in non-small cell lung Cancer. Clin Cancer Res 21(17):4014–4021. https://doi.org/10.1158/1078-0432.CCR-15-0016

    Article  CAS  PubMed  Google Scholar 

  32. Pan ZK, Ye F, Wu X, An HX, Wu JX (2015) Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis. J Thorac Dis 7(3):462–470. https://doi.org/10.3978/j.issn.2072-1439.2015.02.13

    Article  PubMed  PubMed Central  Google Scholar 

  33. Yang H, Chen H, Luo S, Li L, Zhou S, Shen R, Lin H, Xie X (2017) The correlation between programmed death-ligand 1 expression and driver gene mutations in NSCLC. Oncotarget 8(14):23517–23528. https://doi.org/10.18632/oncotarget.15627

    Article  PubMed  PubMed Central  Google Scholar 

  34. D'Incecco A, Andreozzi M, Ludovini V, Rossi E, Capodanno A, Landi L, Tibaldi C, Minuti G, Salvini J, Coppi E, Chella A, Fontanini G, Filice ME, Tornillo L, Incensati RM, Sani S, Crino L, Terracciano L, Cappuzzo F (2015) PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer 112(1):95–102. https://doi.org/10.1038/bjc.2014.555

    Article  CAS  PubMed  Google Scholar 

  35. Li J, Chen Y, Shi X, Le X, Feng F, Chen J, Zhou C, Chen Y, Wen S, Zeng H, Chen AM, Zhang Y (2017) A systematic and genome-wide correlation meta-analysis of PD-L1 expression and targetable NSCLC driver genes. J Thorac Dis 9(8):2560–2571. https://doi.org/10.21037/jtd.2017.07.117

    Article  PubMed  PubMed Central  Google Scholar 

  36. Wang A, Wang HY, Liu Y, Zhao MC, Zhang HJ, Lu ZY, Fang YC, Chen XF, Liu GT (2015) The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis. Eur J Surg Oncol 41(4):450–456. https://doi.org/10.1016/j.ejso.2015.01.020

    Article  CAS  PubMed  Google Scholar 

  37. Kim MY, Koh J, Kim S, Go H, Jeon YK, Chung DH (2015) Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: comparison with tumor-infiltrating T cells and the status of oncogenic drivers. Lung Cancer 88(1):24–33. https://doi.org/10.1016/j.lungcan.2015.01.016

    Article  PubMed  Google Scholar 

  38. Okita R, Maeda A, Shimizu K, Nojima Y, Saisho S, Nakata M (2017) PD-L1 overexpression is partially regulated by EGFR/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer. Cancer Immunol Immunother 66(7):865–876. https://doi.org/10.1007/s00262-017-1986-y

    Article  CAS  PubMed  Google Scholar 

  39. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA (2014) Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 20(19):5064–5074. https://doi.org/10.1158/1078-0432.CCR-13-3271

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Kerr KM, Tsao MS, Nicholson AG, Yatabe Y, Wistuba II, Hirsch FR, Committee IP (2015) Programmed death-ligand 1 immunohistochemistry in lung Cancer: in what state is this art? J Thorac Oncol 10(7):985–989. https://doi.org/10.1097/JTO.0000000000000526

    Article  CAS  PubMed  Google Scholar 

  41. Hong S, Chen N, Fang W, Zhan J, Liu Q, Kang S, He X, Liu L, Zhou T, Huang J, Chen Y, Qin T, Zhang Y, Ma Y, Yang Y, Zhao Y, Huang Y, Zhang L (2016) Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients. Oncoimmunology 5(3):e1094598. https://doi.org/10.1080/2162402X.2015.1094598

    Article  CAS  PubMed  Google Scholar 

  42. Chen N, Fang W, Lin Z, Peng P, Wang J, Zhan J, Hong S, Huang J, Liu L, Sheng J, Zhou T, Chen Y, Zhang H, Zhang L (2017) KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma. Cancer Immunol Immunother 66:1175–1187. https://doi.org/10.1007/s00262-017-2005-z

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Li D, Zhu X, Wang H, Li N (2017) Association between PD-L1 expression and driven gene status in NSCLC: a meta-analysis. Eur J Surg Oncol 43(7):1372–1379. https://doi.org/10.1016/j.ejso.2017.02.008

    Article  CAS  PubMed  Google Scholar 

  44. Haratani K, Hayashi H, Tanaka T, Kaneda H, Togashi Y, Sakai K, Hayashi K, Tomida S, Chiba Y, Yonesaka K, Nonagase Y, Takahama T, Tanizaki J, Tanaka K, Yoshida T, Tanimura K, Takeda M, Yoshioka H, Ishida T, Mitsudomi T, Nishio K, Nakagawa K (2017) Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment. Ann Oncol 28(7):1532–1539. https://doi.org/10.1093/annonc/mdx183

    Article  CAS  PubMed  Google Scholar 

  45. Madore J, Strbenac D, Vilain R, Menzies AM, Yang JY, Thompson JF, Long GV, Mann GJ, Scolyer RA, Wilmott JS (2016) PD-L1 negative status is associated with lower mutation burden, differential expression of immune-related genes, and worse survival in stage III melanoma. Clin Cancer Res 22(15):3915–3923. https://doi.org/10.1158/1078-0432.CCR-15-1714

    Article  CAS  PubMed  Google Scholar 

  46. Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, Mikse OR, Cherniack AD, Beauchamp EM, Pugh TJ, Wilkerson MD, Fecci PE, Butaney M, Reibel JB, Soucheray M, Cohoon TJ, Janne PA, Meyerson M, Hayes DN, Shapiro GI, Shimamura T, Sholl LM, Rodig SJ, Freeman GJ, Hammerman PS, Dranoff G, Wong KK (2013) Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 3(12):1355–1363. https://doi.org/10.1158/2159-8290.CD-13-0310

    Article  CAS  PubMed  Google Scholar 

  47. Chen N, Fang W, Zhan J, Hong S, Tang Y, Kang S, Zhang Y, He X, Zhou T, Qin T, Huang Y, Yi X, Zhang L (2015) Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC: implication for optional immune targeted therapy for NSCLC patients with EGFR mutation. J Thorac Oncol 10(6):910–923. https://doi.org/10.1097/JTO.0000000000000500

    Article  CAS  PubMed  Google Scholar 

  48. Lastwika KJ, Wilson W, 3rd, Li QK, Norris J, Xu H, Ghazarian SR, Kitagawa H, Kawabata S, Taube JM, Yao S, Liu LN, Gills JJ, Dennis PA (2016) Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung Cancer. Cancer Res 76 (2):227–238. https://doi.org/10.1158/0008-5472.CAN-14-3362

  49. O'Kane GM, Bradbury PA, Feld R, Leighl NB, Liu G, Pisters KM, Kamel-Reid S, Tsao MS, Shepherd FA (2017) Uncommon EGFR mutations in advanced non-small cell lung cancer. Lung Cancer 109:137–144. https://doi.org/10.1016/j.lungcan.2017.04.016

    Article  PubMed  Google Scholar 

  50. Peters S, Creelan BD, Hellmann M, Socinski M, Reck M, Bhagavatheeswaran P, Chang HJ, Geese W, Paz-Ares L, Carbone D (2017) Abstract CT082: Impact of tumor mutation burden on the efficacy of first-line nivolumab in stage iv or recurrent non-small cell lung cancer: An exploratory analysis of CheckMate 026, 77. https://doi.org/10.1158/1538-7445.AM2017-CT082

Download references

Author information

Authors and Affiliations

  1. Molecular Pathology Diagnostic Service, Queen Elizabeth Hospital Birmingham, Mindelsohn Way, Birmingham, B15 2TH, UK

    Matthew Evans, Brendan O’Sullivan, Frances Hughes, Tina Mullis, Matthew Smith, Nicola Trim & Philippe Taniere

Authors
  1. Matthew Evans
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brendan O’Sullivan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Frances Hughes
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tina Mullis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Matthew Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nicola Trim
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Philippe Taniere
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthew Evans.

Ethics declarations

Conflicts of Interest

All Authors Declare that they Have no Conflict of Interest

Electronic supplementary material

ESM 1

(PDF 79 kb)

ESM 2

(PDF 89 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Evans, M., O’Sullivan, B., Hughes, F. et al. The Clinicopathological and Molecular Associations of PD-L1 Expression in Non-small Cell Lung Cancer: Analysis of a Series of 10,005 Cases Tested with the 22C3 Assay. Pathol. Oncol. Res. 26, 79–89 (2020). https://doi.org/10.1007/s12253-018-0469-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-018-0469-6

Keywords

Search

Navigation